Xilio Therapeutics (XLO) Accumulated Expenses (2020 - 2026)

Xilio Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $9.0 million in Q1 2026.

• Quarterly Accumulated Expenses rose 131.01% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 131.01% YoY) and the FY2025 annual result came in at $11.7 million, up 17.61% from the prior year.
• Accumulated Expenses retreated to $9.0 million in Q1 2026 per XLO's latest filing, from $11.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.1 million in Q2 2022 and troughed at $15000.0 in Q3 2024.
• A 5-year average of $8.2 million and a median of $9.0 million in 2026 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 99.84% in 2024, then soared 59580.0% in 2025.
• Over 5 years, Accumulated Expenses stood at $10.3 million in 2022, then rose by 1.65% to $10.5 million in 2023, then fell by 4.92% to $10.0 million in 2024, then advanced by 17.61% to $11.7 million in 2025, then slipped by 23.59% to $9.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $9.0 million, $11.7 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.